Risultati della ricerca - Jonathan Webster

  • Mostra 1 - 13 risultati su 13
Raffina i risultati
  1. 1
    Acute myeloid leukemia in the elderly: therapeutic options and choice

    Acute myeloid leukemia in the elderly: therapeutic options and choice di Jonathan Webster, Keith W. Pratz

    Pubblicazione 2017
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease

    Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease di Lucy Walkington, Jonathan Webster, B. W. Hancock, Jan Everard, Robert E. Coleman

    Pubblicazione 2011
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    Mobile app validation: a digital health scorecard approach

    Mobile app validation: a digital health scorecard approach di Ramy Sedhom, Michael McShea, Adam B. Cohen, Jonathan Webster, Simon C. Mathews

    Pubblicazione 2021
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea

    A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea di Jonathan Webster, G. Piscitelli, Anna Polli, Carlo Ferrari, Ikram Shah Ismail, M. F. Scanlon

    Pubblicazione 1994
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion.

    Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. di Sadanori Akita, Jonathan Webster, Shaolei Ren, Hirofumi Takino, Joanne Said, O Zand, Шломо Мелмед

    Pubblicazione 1995
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    DNA methyltransferase inhibitor exposure–response: Challenges and opportunities

    DNA methyltransferase inhibitor exposure–response: Challenges and opportunities di Amanda B. Kagan, Dominique A. Garrison, Nicole M. Anders, Jonathan Webster, Sharyn D. Baker, Srinivasan Yegnasubramanian, Michelle A. Rudek

    Pubblicazione 2023
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  7. 7
    Hydroxylated chalcones with dual properties: Xanthine oxidase inhibitors and radical scavengers

    Hydroxylated chalcones with dual properties: Xanthine oxidase inhibitors and radical scavengers di Emily Hofmann, Jonathan Webster, Thuy Do, Reid Kline, Lindsey Snider, Quintin Hauser, Grace Higginbottom, Austin Campbell, Lili Ma, Stefan Paula

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ

    Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ di Mimansa Sharma, Andrew H. Beck, Jonathan Webster, I Espinosa, Kelli Montgomery, Sushama Varma, Matt van de Rijn, Kristin C. Jensen, Robert B. West

    Pubblicazione 2009
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Chaperone Activity of Small Heat Shock Proteins Underlies Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis

    Chaperone Activity of Small Heat Shock Proteins Underlies Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis di Michael Kurnellas, Sara E. Brownell, Leon Su, Andrey V. Malkovskiy, Jayakumar Rajadas, Gregory Dolganov, Sidharth Chopra, Gary K. Schoolnik, Raymond A. Sobel, Jonathan Webster, Shalina S. Ousman, Rachel A. Becker, Lawrence Steinman, Jonathan B. Rothbard

    Pubblicazione 2012
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers: A Prospective, Cross-Sectional, Multicenter Study

    Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers: A Prospective, Cross-Sectional, Multicenter... di Jeffrey I. Zwicker, Adam Rojan, Federico Campigotto, Nadia Rehman, Renee Funches, Gregory C. Connolly, Jonathan Webster, Anita Aggarwal, Dalia Mobarek, Charles Faselis, Donna Neuberg, Frederick R. Rickles, Ted Wun, Michael B. Streiff, Alok A. Khorana

    Pubblicazione 2014
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia

    Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia di Jonathan Webster, Raoul Tibes, Larry Morris, Amanda L. Blackford, Mark R. Litzow, Mrinal M. Patnaik, Gary L. Rosner, Ivana Gojo, Robert J. Kinders, Lihua Wang, L. Austin Doyle, Catherine J. Huntoon, Larry M. Karnitz, Scott H. Kaufmann, Judith E. Karp, B. Douglas Smith

    Pubblicazione 2017
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

    Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML... di Ivana Gojo, Robert K. Stuart, Jonathan Webster, Amanda L. Blackford, Juan Carlos Varela, Jillian Morrow, Amy E. DeZern, Matthew C. Foster, Mark J. Levis, Catherine C. Coombs, Gabrielle T. Prince, B. Douglas Smith, Hendrik W. van Deventer, Katarzyna Jamieson, Ravi Varadhan, Benjamin G. Vincent, Jonathan S. Serody, Leo Luznik, Joshua F. Zeidner

    Pubblicazione 2019
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

    Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia di Joshua F. Zeidner, Benjamin G. Vincent, Anastasia Ivanova, Dominic T. Moore, Karen P. McKinnon, Alec Wilkinson, Rupkatha Mukhopadhyay, Francesco Mazziotta, Hanna A. Knaus, Matthew C. Foster, Catherine C. Coombs, Katarzyna Jamieson, Hendrik Van Deventer, Jonathan Webster, Gabrielle T. Prince, Amy E. DeZern, B. Douglas Smith, Mark J. Levis, Nathan D. Montgomery, Leo Luznik, Jonathan S. Serody, Ivana Gojo

    Pubblicazione 2021
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: